Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

Javier Molina-Cerrillo; Teresa Alonso-Gordoa; Alfredo Carrato; Enrique Grande

doi:10.18632/oncotarget.28312

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

PDF | How to cite

Oncotarget. 2022; 13:1245-1245. https://doi.org/10.18632/oncotarget.28312

Metrics: PDF 492 views | ?

Javier Molina-Cerrillo¹, Teresa Alonso-Gordoa¹, Alfredo Carrato¹ and Enrique Grande²

¹Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
²MD Anderson Cancer Center, Madrid, Spain

Published: November 17, 2022

Copyright: © 2022 Molina-Cerrillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The patient provided written informed consent.

Original article: Oncotarget. 2020; 11:2137–2140. DOI: https://doi.org/10.18632/oncotarget.27598

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28312

Publication Alerts

Addendum:

Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation